Hyperlipidemia Impairs Osseointegration via the ROS/Wnt/β-Catenin Pathway. (June 2021)

• Record Type: Journal Article
• Authors: Wang, Y.N.; Jia, T.T.; Feng, Y.; Liu, S.Y.; Zhang, W.J.; Zhang, D.J.; Xu, X.
• Is Part Of: Journal of dental research. Volume 100:Number 6(2021)
• Page Start: 658
• Page End: 665
• Publication Date: 2021-06
• Subjects: dental implants -- oxidative stress -- osteoblast -- osteogenesis -- signal transduction -- animal disease model; Dentistry -- Periodicals; Dentistry -- Social aspects -- Periodicals; Dentistry -- Periodicals; Research -- Periodicals; 617.6005
• DOI: 10.1177/0022034520983245
• Languages: English
• ISSNs: 0022-0345

Abstract

The influence of hyperlipidemia on titanium implant osseointegration and the underlying mechanisms is not well understood. This study investigates the changes in osseointegration and explores the potential mechanisms in hyperlipidemia conditions. In vivo, specialized titanium implants were implanted in the femurs of diet-induced or genetic hyperlipidemia mice. In vitro, primary murine osteoblasts were cultured on the titanium surface in high-fat medium. Results showed that hyperlipidemia led to poor osseointegration in both types of mice in vivo, and high-fat medium impaired the osteogenic differentiation of primary osteoblasts on the titanium surface in vitro. In addition, high-fat medium caused significant overproduction of reactive oxygen species (ROS) and inhibition of the Wnt/β-catenin pathway in osteoblasts. Both N-acetyl-L-cysteine (NAC, an ROS antagonist) and Wnt3a (an activator of the Wnt/β-catenin pathway) attenuated the poor osteogenic ability of osteoblasts. In addition, NAC reactivated the Wnt/β-catenin pathway in osteoblasts under high-fat stimulation. These results demonstrate that hyperlipidemia impairs osseointegration via the ROS/Wnt/β-catenin pathway and provide support for the ROS or Wnt/β-catenin pathway as a promising therapeutic target for the development of novel drugs or implant materials to improve the osseointegration of implants in hyperlipidemic patients.